Cholesterol and blood fats
N-acetylcysteineand LDL cholesterol
Both sources here found no clear difference in LDL cholesterol.
How sure anyone can be
Low certainty, level 2 of 4Further research is likely to change this.
The most certain of the two findings here; each record carries its own.
The numbers reported
No number has been put on this yet. Two sources recorded only which way the numbers went — for now, that is all we have here.
Two sources, newest first
What we read is the published abstract, not the full paper, so a blank below may still be printed in the paper itself. A fixed rule worked this out from the source’s own fields. Nobody checked this rating by hand.
Randomised trial, 2025
Low certainty, level 2 of 4Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial.
Addict Health. 2025;17:1667. doi:10.34172/ahj.1667. PMID:41431629.
- Number reported
- Not in the abstract
- Which way it went
- No clear difference
- Likely range
- Not in the abstract
- Source’s own words
- LDL-C vs placebo; no significant between-group change; magnitude not given
- Who was studied
- Patients with MASLD
- Compared with
- placebo
- Amount taken
- 600 mg, administered three times daily
- For how long
- Not in the abstract
- Disagreement between studies
- Not in the abstract
- Kind of record
- Journal article
How this rating was reachedstarts at High, 2 steps down: risk of bias and imprecision
- Starts at High
- Risk of bias brought it down to Moderatethe abstract reports no risk-of-bias or quality appraisal, so study limitations cannot be ruled outNot in the abstract
- Imprecision brought it down to Lowthe abstract reports no confidence interval for the estimateNot in the abstract
- Ends at Low2 steps down.
- Checked, nothing to step it down for
- indirectness
- Inconsistency
- One study, so there was nothing to disagree
Imprecision stops at the first check that applies; others may apply too.
Source saved; quote checked byte-for-byte against it by software; no signature.
Randomised trial, 2022
Low certainty, level 2 of 4Effects of N-acetylcysteine supplementation on disease activity, oxidative stress, and inflammatory and metabolic parameters in rheumatoid arthritis patients: a randomized double-blind placebo-controlled trial.
Amino Acids. 2022;54(3):433-440. doi:10.1007/s00726-022-03134-8. PMID:35133468.
- Number reported
- Not in the abstract
- Which way it went
- No clear difference
- Likely range
- Not in the abstract
- Source’s own words
- LDL-C vs placebo; no significant between-group change; magnitude not given
- Who was studied
- Adult with rheumatoid arthritis
- Compared with
- placebo
- Amount taken
- 1,200 mg/d (600 mg twice daily)
- For how long
- 91 days
- Disagreement between studies
- Not in the abstract
- Kind of record
- Journal article
How this rating was reachedstarts at High, 2 steps down: risk of bias and imprecision
- Starts at High
- Risk of bias brought it down to Moderatethe abstract reports no risk-of-bias or quality appraisal, so study limitations cannot be ruled outNot in the abstract
- Imprecision brought it down to Lowthe abstract reports no confidence interval for the estimateNot in the abstract
- Ends at Low2 steps down.
- Checked, nothing to step it down for
- indirectness
- Inconsistency
- One study, so there was nothing to disagree
Imprecision stops at the first check that applies; others may apply too.
AI review could not confirm it — an AI agent re-read this finding against the saved source and at least one check failed. The batch record names the check and quotes the sentence that caused the doubt. No person read it.
What is still missing from these readings
- None gives a number at all, only which way it went.
- Two give no likely range, so how precise those numbers are is unknown.
- Two do not say how many people took part.
- For how long — One of Two readings: Not in the abstract.
Something nobody wrote down is never a zero and never a guess.
Still to read for N-acetylcysteine
Seven of the 18 things on our list for N-acetylcysteine have no reading here yet:
- Alanine aminotransferase (ALT)
- Aspartate aminotransferase (AST)
- Cycling Functional Threshold Power
- Cycling Power
- Diastolic blood pressure
- HOMA-IR
- Systolic blood pressure
Still to read means nobody here has got to it, not that it was tried and did nothing or that no research exists. A pairing on no list is not a gap: we never set out to read it.
Read next
N-acetylcysteine
Ten other questions read for it
Cholesterol and blood fats
70 questions read under it
LDL cholesterol
19 other ingredients read against it
First six, alphabetical, and by nothing else. The rest are on Cholesterol and blood fats.
This is a library, not advice. No recommendation, no dose, no diagnosis, no ranking. We never ask about your symptoms, and nothing here is tailored to you.